These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 31080204)
41. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient. Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679 [TBL] [Abstract][Full Text] [Related]
42. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. Alcalay J; Tauber G; Fenig E; Hodak E J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842 [TBL] [Abstract][Full Text] [Related]
43. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Dreno B; Basset-Seguin N; Caro I; Yue H; Schadendorf D Oncologist; 2014 Aug; 19(8):790-6. PubMed ID: 25001266 [TBL] [Abstract][Full Text] [Related]
44. Vismodegib in basal cell carcinoma. Amaria RN; Bowles DW; Lewis KD; Jimeno A Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657 [TBL] [Abstract][Full Text] [Related]
45. Amenorrhea secondary to a vismodegib-induced blockade of follicle-stimulating hormone-receptor activation. Strasswimmer J; Latimer B; Ory S Fertil Steril; 2014 Aug; 102(2):555-7. PubMed ID: 24890268 [TBL] [Abstract][Full Text] [Related]
46. Discovery and preclinical development of vismodegib. Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041 [TBL] [Abstract][Full Text] [Related]
47. Vismodegib for the treatment of basal cell skin cancer. Poggi L; Kolesar JM Am J Health Syst Pharm; 2013 Jun; 70(12):1033-8. PubMed ID: 23719880 [TBL] [Abstract][Full Text] [Related]
48. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. Zhu GA; Sundram U; Chang AL JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281 [TBL] [Abstract][Full Text] [Related]
49. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma. Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414 [TBL] [Abstract][Full Text] [Related]
50. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression. Maier T; Kulichova D; Ruzicka T; Berking C J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708 [TBL] [Abstract][Full Text] [Related]
51. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. Tauber G; Pavlovsky L; Fenig E; Hodak E J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385 [TBL] [Abstract][Full Text] [Related]
52. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas. Sobanko JF; Okman J; Miller C J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062 [TBL] [Abstract][Full Text] [Related]
54. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib. Poulalhon N; Dalle S; Balme B; Thomas L Dermatology; 2015; 230(2):101-4. PubMed ID: 25633488 [TBL] [Abstract][Full Text] [Related]